Mr. Amin was appointed as Chief Financial and Strategy Officer of Pyramid Biosciences in August 2022. Prior to joining Pyramid Bio, he served as Chief Financial Officer of Immuneering Corporation (Nasdaq: IMRX), where he successfully led a $120 million IPO in 2021. Previously Mr. Amin spent nearly two decades on Wall Street, where he built a strong track record covering small-mid cap biotechnology companies, focusing on oncology, CNS disorders, ophthalmology and rare diseases. Mr. Amin spent ten years at Jefferies Financial Group as Managing Director in their Equity Research group. During this time, he was named Best Stock Picker in Biotechnology in 2013 by Financial Times. Prior to joining Jefferies, Mr. Amin was an equity research analyst covering biotechnology and pharmaceuticals at several firms including Prudential Equity Group. He started his career at Aventis Pharmaceuticals (currently part of Sanofi) where he served as the Senior Manager in their Scientific Competitive Intelligence group. Mr. Amin received his B.S. in pharmacy from the University of the Sciences in Philadelphia, his M.S. in pharmacy from Long Island University and his M.B.A. from the Stern School of Business at New York University.